Treatment of basal cell carcinomas with intralesional recombinant interferonα-2b

Each of 21 patients with histologically proven basal cell carcinomas received three injections of 1.5 106 U recombinant interferona-2b per week for 3 weeks. Excision biopsies were performed 3 months after completion of treatment. Eight out of 19 biopsies revealed no evidence of residual tumour and 12 out of 20 patients experienced some side-effects considered mild by both patient and investigator in most cases.